Andrew Hui

biotech is pretty interesting
read our research @

[Andrew Hui @backshui]

Testing a longer-form research format away from the usual slide decks on bio-data for model training. Putting some highlights in the thread.
https://t.co/CRfbL74nyo

[Andrew Hui @backshui]

@mkoeris @andrewhedin @grace__dai @BessemerVP https://t.co/KBPrUyOuUK
keen to hear your thoughts on our research

[Andrew Hui @backshui]

@brad_woolf what is the source?

[Andrew Hui @backshui]

some coverage on chai from @Contrary_Res https://t.co/kDoIIPBlj6

[Andrew Hui @backshui]

to nobody's surprise,@chaidiscovery is a big TWST customer as training bio foundation models need training data

[Andrew Hui @backshui]

@ShahramSN but the whole business is built on retail hype??

[Andrew Hui @backshui]

chat is this chatgpt?

[Andrew Hui @backshui]

3 years ago... how we feeling about proteomics?

[Andrew Hui @backshui]

@AppleHelix is it corporate strategy or marketing strategy? I would argue rxrx is retail-forward and gets rewarded with a better valuation while sdgr is perceived as boring legacy-saas

both businesses arguably have very similar corporate strategies and have pivoted to asset development

[Andrew Hui @backshui]

underrated point of the ajax story is that schrodinger owned a sizable equity stake - as with structure therapeutics (3.2B), Morphic (acquired 3.2B), among others...

If they were a VC fund they would be taking victory laps, unfortunately they're a SaaS business...

[The Wall Street Journal @WSJ]

Eli Lilly continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer portfolio. https://t.co/0G3YkcilV8

[Andrew Hui @backshui]

@LifeSciLad offer still drastically under cash on balance sheet though, would be brutal if it goes through

[Andrew Hui @backshui]

@LifeSciLad >1b market cap, big day for life science tooling?

[Andrew Hui @backshui]

@two_natural lots of people chasing this opportunity so you would have to assume so, there are preclinical "techbio" competitors like Recursion and Genesis Therapeutics going after the same target as well

[Andrew Hui @backshui]

@JulianKlymochko That’s why they have a pretty website 🙂

[Andrew Hui @backshui]

@buccocapital Peloton up because Anthropic enables better workouts..?

[Andrew Hui @backshui]

@mkoeris Similar findings from this recent preprint as well https://t.co/k6P31fGoa8

[Andrew Hui @backshui]

@MelindaBChu1 the ones that do pivot to drug development end up crowding the same targets anyways (e.g. PI3Ka mutant inhibitors)

[Andrew Hui @backshui]

@packyM had a sick lab tour last year from them, very cool work

[Andrew Hui @backshui]

Biotech funding (US/China/Global)

[Andrew Hui @backshui]

China biotech funding

[Andrew Hui @backshui]

TL;DR
AI performance is tied to scaling laws, which means more data going in, hence, "data problems". The next wave of value creation will be tied to new sources of data that explore new biological space. But the issue is that this data isn't readily available for the industry.

[Andrew Hui @backshui]

Testing a longer-form research format away from the usual slide decks on bio-data for model training. Putting some highlights in the thread.
https://t.co/CRfbL74nyo

[Andrew Hui @backshui]

8/ Scaling generative models drives the cost of hypothesis generation to zero. However, the key is still wet lab validation. The gap between hypothesis generation and wet lab validation creates "speculation debt" that still needs to be bridged